1. Home
  2. SANG vs LCTX Comparison

SANG vs LCTX Comparison

Compare SANG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SANG
  • LCTX
  • Stock Information
  • Founded
  • SANG 1984
  • LCTX 1990
  • Country
  • SANG Canada
  • LCTX United States
  • Employees
  • SANG N/A
  • LCTX N/A
  • Industry
  • SANG Computer Software: Programming Data Processing
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SANG Technology
  • LCTX Health Care
  • Exchange
  • SANG Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • SANG 170.7M
  • LCTX 165.6M
  • IPO Year
  • SANG 2021
  • LCTX N/A
  • Fundamental
  • Price
  • SANG $6.34
  • LCTX $0.88
  • Analyst Decision
  • SANG Buy
  • LCTX Strong Buy
  • Analyst Count
  • SANG 2
  • LCTX 3
  • Target Price
  • SANG $5.63
  • LCTX $5.67
  • AVG Volume (30 Days)
  • SANG 8.0K
  • LCTX 294.4K
  • Earning Date
  • SANG 09-18-2024
  • LCTX 11-07-2024
  • Dividend Yield
  • SANG N/A
  • LCTX N/A
  • EPS Growth
  • SANG N/A
  • LCTX N/A
  • EPS
  • SANG N/A
  • LCTX N/A
  • Revenue
  • SANG $250,030,000.00
  • LCTX $6,186,000.00
  • Revenue This Year
  • SANG N/A
  • LCTX N/A
  • Revenue Next Year
  • SANG $3.05
  • LCTX $119.00
  • P/E Ratio
  • SANG N/A
  • LCTX N/A
  • Revenue Growth
  • SANG N/A
  • LCTX N/A
  • 52 Week Low
  • SANG $2.18
  • LCTX $0.77
  • 52 Week High
  • SANG $6.40
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • SANG 70.22
  • LCTX 47.12
  • Support Level
  • SANG $5.15
  • LCTX $0.83
  • Resistance Level
  • SANG $5.50
  • LCTX $0.94
  • Average True Range (ATR)
  • SANG 0.25
  • LCTX 0.05
  • MACD
  • SANG 0.09
  • LCTX 0.00
  • Stochastic Oscillator
  • SANG 97.18
  • LCTX 45.45

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable Internet protocol communications systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes Cloud Services, Video Conferencing, Carrier Services, Business Phone Systems, Phones & Devices, and Network Connectivity. The company sells into three major geographic centers: the United States of America, which is the key revenue driver, Canada, and other foreign countries.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: